London Genetics Ltd., a not-for-profit, grant-funded company set up in 2007 to give pharmacogenetic advice to drug developers, has appointed its first management team.
Barrie Ward, a director of several pharmaceutical companies, has been appointed chairman. Dominique Kleyn, who previously headed the bioscience business development, technology transfer and new venture teams at the Imperial College London, becomes chief executive. Mark Caulfield, an expert in the genetics of cardiovascular disease, has been named clinical director.
Contacted by telephone, Ms Kleyn said that Britain has a vast pool of geneticists whose expertise can be tapped to predict probable side effects of drugs under development. “What we are really trying to do is hit the sweet spot between academic and clinical research,” she said.
Copyright 2009 Evernow Publishing Ltd